| Name | Title | Contact Details |
|---|
Intellect Neurosciences Inc. is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of Aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Aramchol is initially being developed for treating Non-Alcoholic Steato-hepatitis, or NASH, a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. Galmed Pharmaceuticals Galmed’s business has been, in its current legal structure, was incorporated in Israel on July 31, 2013 as a privately held company. However, operating since 2000 under a different group of companies established in the same year. Galmed was co-founded by Professor Tuvia Gilat and Allen Baharaff, based on Professor Gilat’s extensive research in FABAC’s and NASH.
Cardiology Associates of Alabama offers vascular care and heart treatments including structural heart, interventional procedures, pediatric cardiology, heart rhythm disorders, and congestive heart failure.
Summers Laboratories Inc. is a Collegeville, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Visus Therapeutics is a clinical-stage company in pursuit of developing the world`s first presbyopia-correcting eye drop with the potential to last at least eight hours. With offices in Seattle, Washington, and Orange County, California, our lead clinical candidate is VTI-001 (BRIMOCHOL™), a once-daily eye drop designed to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates.